M
Matthew C. Thomas
Researcher at Johns Hopkins University
Publications - 11
Citations - 858
Matthew C. Thomas is an academic researcher from Johns Hopkins University. The author has contributed to research in topics: Immune system & Cancer. The author has an hindex of 9, co-authored 11 publications receiving 809 citations. Previous affiliations of Matthew C. Thomas include Johns Hopkins University School of Medicine.
Papers
More filters
Journal ArticleDOI
The immunodominant major histocompatibility complex class I-restricted antigen of a murine colon tumor derives from an endogenous retroviral gene product.
Alex Yee-Chen Huang,Pamela H. Gulden,Amina S. Woods,Matthew C. Thomas,Caryn D. Tong,Wei Wang,Victor H. Engelhard,Gary R. Pasternack,Robert J. Cotter,Donald F. Hunt,Drew M. Pardoll,Elizabeth M. Jaffee +11 more
TL;DR: Adoptive transfer with CTL lines specific for this antigen demonstrated that this epitope represents a potent tumor rejection antigen, providing evidence for a unique class of shared immunodominant tumor associated antigens as targets for antitumor immunity.
Journal Article
Development and characterization of a cytokine-secreting pancreatic adenocarcinoma vaccine from primary tumors for use in clinical trials.
Elizabeth M. Jaffee,Mieke Schutte,Jeanette Gossett,Laura Morsberger,Adam J. Adler,Matthew C. Thomas,Tim F. Greten,Ralph H. Hruban,Charles J. Yeo,Constance A. Griffin +9 more
TL;DR: The findings suggest that allogeneic as well as autologous tumor cells can be used as the tumor source for developing cancer vaccines, and a method for the routine generation of in vitro cell lines from primary tumors of the pancreas is developed.
Journal ArticleDOI
PIK3CA and AKT1 Mutations Have Distinct Effects on Sensitivity to Targeted Pathway Inhibitors in an Isogenic Luminal Breast Cancer Model System
Julia A. Beaver,John P. Gustin,Kyung H. Yi,Anandita Rajpurohit,Matthew C. Thomas,Sam J. Gilbert,D. Marc Rosen,Ben Ho Park,Josh Lauring +8 more
TL;DR: AKT1 E17K is a bona fide oncogene in a human luminal breast cancer context and has implications for the use of tumor genome sequencing to assign patients to targeted therapies.
Journal ArticleDOI
Enhanced Tumor Protection by Granulocyte-Macrophage Colony-Stimulating Factor Expression at the Site of an Allogeneic Vaccine
TL;DR: Results demonstrate that the expression of an allogeneic MHC molecule by a vaccine cell can actually enhance the induction of systemic antitumor immunity, and support the design of clinical trials for testing this more feasible and generalizable whole tumor cell vaccine approach.
Journal ArticleDOI
Enhanced immune priming with spatial distribution of paracrine cytokine vaccines
Elizabeth M. Jaffee,Matthew C. Thomas,Alex Yee-Chen Huang,Karen M. Hauda,Hyam I. Levitsky,Drew M. Pardoll +5 more
TL;DR: The murine model is used to identify a number of parameters that may be critical for enhancing vaccine efficacy, including antigen dose and cytokine level, and the distribution of vaccine inoculation was found to have a significant impact on vaccine potency.